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ABSTRACT 
Background: It is unclear if polypharmacy is associated with incident frailty. Thus, we investigated 
whether polypharmacy is associated with a higher incidence of frailty in a large cohort of North 
Americans over eight years of follow-up. 
Methods: Details regarding medication prescription were captured and categorized as: 0-3, 4-6, and 
>7. Frailty was defined using the Study of Osteoporotic Fracture (SOF) index as the presence of ≥2 
out of: (i) weight loss >5% between baseline and the subsequent follow-up visit; (ii) inability to do 
five chair stands; (iii) low energy level according to the SOF definition. Cox’s regression models 
calculating a hazard ratio (HR) with 95% confidence intervals (CIs), adjusted for potential 
confounders, were undertaken. 
Results: During the 8-year follow-up, from 4,402 participants at baseline, 361 became frail. 
Compared to participants taking 0-3 medications, the incidence of frailty was approximately double 
in those taking 4-6 medications and six times higher in people taking > 7 medications. After 
adjusting for 11 potential baseline confounders, participants using 4-6 medications had a higher risk 
of frailty of 55% (HR=1.55; 95%CI: 1.22-1.96; p<0.0001), whilst those using more than 7 drugs 
were at approximately 147% (HR=2.47; 95%CI: 1.78-3.43; p<0.0001). Each additional drug used at 
the baseline increased the risk of frailty at the follow-up of 11% (HR=1.11; 95%CI: 1.07-1.15; 
p<0.0001). 
Conclusions: Polypharmacy is associated with a higher incidence of frailty over 8-year follow-up 
period. Our data suggest evidence of a dose response relationship. Future research is required to 
confirm our findings and explore underlying mechanisms. 
 
Keywords: frailty; polypharmacy; frail, medication, older adult  
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INTRODUCTION 
Frailty is usually defined as “a state of increased vulnerability to stressors resulting from a decrease 
in physiologic reserves in multiple organ systems causing limited capacity to maintain 
homeostasis”.1 Frailty has been associated with an increased risk of several deleterious outcomes in 
older people, including disability, falls, hospitalization, institutionalization and death. 1 Recent 
studies have however suggested that frailty could be considered an independent risk factor for 
cardiovascular2 and metabolic3 diseases that could further increase the transition from frailty to 
disability. Unsurprisingly, the prevention of frailty is an international priority, therefore the search 
for potential risk factors is of utmost importance.   
 
To date, there has been a paucity of research considering the relationship between polypharmacy 
and frailty. Some recent cross-sectional studies found evidence of a strong association between 
polypharmacy and the prevalence of frailty. 4,5 Furthermore, several short-term follow up studies 
have suggested that polypharmacy is associated with a higher risk for incident frailty.6-8 However, 
some limitations are evident with these studies, including the relatively short follow-up period 
(maximum five years) and the small sample sizes. The relationship between polypharmacy and 
frailty is complex, since, whilst several studies have suggested polypharmacy is associated with 
frailty 6-8, others have suggested that  a higher adherence to medications could be associated with 
lower mortality rate in frail older subjects.9-11 Given that frailty is a reversible condition if 
appropriately treated 12, understanding if polypharmacy is associated with incident frailty could be 
of public health importance. 
 
The current study aimed to investigate whether polypharmacy is associated with a higher incidence 
of frailty in a large cohort of North Americans participating in the Osteoarthritis Initiative over 
eight years of follow-up. We hypothesized that higher number of medications is associated with a 
higher incidence of frailty.   
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MATERIALS AND METHODS 
Data source and subjects 
Data were obtained from the Osteoarthritis Initiative (OAI) database, which is available for public 
access at http://www.oai.ucsf.edu/. The specific datasets utilized were registered during the baseline 
and screening evaluations (V00) and each database reporting data on frailty until 96 months from 
baseline (V10).  Patients at high risk of knee OA were recruited at four clinical centers in the USA 
(Baltimore, MD; Pittsburgh, PA; Pawtucket, RI; and Columbus, OH) between February 2004 and 
May 2006.  
All the participants provided written informed consent. The OAI study protocol was approved by 
the institutional review board of the OAI Coordinating Center, University of California at San 
Francisco. 
 
Number of medications (exposure) 
A specific questionnaire investigating the name of the prescription medicine, duration of use, 
formulation code (oral, rectal, topical etc.) in the 30 days before the interview was used and the 
number of medications was recorded. Multivitamins’ supplementations were not included. Trained 
interviewers checked the medications used by each participant in the last 30 days. Since there is no 
consistent definition of polypharmacy and the use of numeric threshold has been shown to be too 
simplistic and unhelpful 13, we used the categorization suggested in the development of 
multidimensional prognostic index 14, i.e. 0-3, 4-6 or > 7 medications.  
 
Outcome 
The study’s outcome of interest was incident frailty. In accordance with the Study of Osteoporotic 
Fracture (SOF) index 15,16 frailty was defined as the presence of ≥2 out of three of the following 
criteria: (i) weight loss >5% taking place between baseline and the follow-up examinations (at the 
baseline examination a body mass index, BMI, of less than 20 Kg/m2 was used, since no 
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information regarding weight changes were recorded); (ii) the inability to rise from a chair five 
times without arm support (hereafter referred to as inability to carry out chair stands); and (iii) poor 
energy based on the SF12 questionnaire response of “little at a time” or “none at a time” to the 
question “in the past 4 weeks, did you have a lot of energy?” 
 
Covariates 
We identified 11 potential confounders including BMI; physical activity evaluated using the 
Physical Activity Scale for the Elderly (PASE) 17; race; smoking habits; educational level and 
yearly income (< or > $50,000 and missing data) to assess the relationship between number of 
medications at the baseline and incident frailty. Validated general health measures of self-reported 
comorbidities were assessed using the modified Charlson comorbidity score.18  
 
Since nutritional parameters could be of importance to assess the association between number of 
medications and frailty19, we included as covariates the daily calorie intake and the adherence to 
Mediterranean diet with a validated score.20,21 
 
Statistical analyses 
Normal distributions of continuous variables were tested using the Kolmogorov-Smirnov test. Data 
are shown as means±standard deviations (SD) for quantitative measures, and frequency and 
percentages for all discrete variables. P values for trends were calculated using the Jonckheere-
Terpstra test for continuous variables and the Mantel-Haenszel Chi-square test for categorical ones.  
 
Cox’s regression analysis was used to assess the strength of the association between number of 
medications at baseline and incident frailty. Factors significantly different across number of 
medications categories (considering a p-value<0.10) or significantly associated with incident frailty 
at univariate analysis (p-value<0.05) were included. Multi-collinearity among covariates was 
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assessed using the variance inflation factor (VIF), with a score of 2 leading to the exclusion of a 
variable, but no parameter was excluded for this reason. Age (as continuous); sex; race (whites vs. 
others); body mass index (as continuous); education (degree vs. others); smoking habits (current 
and previous vs. others); yearly income (categorized as > or < 50,000$ and missing data); Physical 
Activity Scale for Elderly score (as continuous); Charlson co-morbidity index (as continuous); daily 
energy intake (as continuous); adherence to Mediterranean diet (as continuous). The proportional 
hazard assumption was verified considering Schoenfeld’s residuals of the covariates.22 Cox’s 
regression analysis data were reported as hazard ratios (HRs) with 95% confidence intervals (CIs). 
A similar analysis was run using the number of medications as continuous variable.  
 
To test the robustness of our findings, sensitivity analyses were conducted evaluating the interaction 
between number of medications and selected factors (e.g. gender, median age, smoking status etc.) 
in predicting frailty onset at follow-up, but no one emerged as significant moderator of our findings.  
 
All the analyses were performed using the SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois). 
All statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05.  
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RESULTS 
Sample selection 
The OAI dataset initially includes a total of 4,796 North American participants. Twenty-one 
participants were excluded due to insufficient information regarding medications and 20 were 
already frail at the baseline. Another 353 were excluded since they do not have data regarding 
incident frailty. Thus, 4,402 participants were finally included in this study.  
 
Descriptive characteristics  
Of the 4,402 participants, 1,844 were males and 2,558 females. Mean age was 61.2 years (±9.2 
years; range: 45-79). The number of medications used across the entire sample was in mean 3 
(range: 0-27).  
  
Table 1 shows the participants’ characteristics classified by the number of medications used. 
Participants using 7 medications or more were significantly older, more likely to be females, 
smokers, poor and less physically active and white compared to those using less medications (p for 
trend<0.0001 for all comparisons). Moreover, those using 7 or more medications were more 
frequently obese and they had a significant higher presence of several co-morbidities (Table 1). 
Finally, they reported a significant higher calorie intake than those using less medications (Table 1).  
Regarding the frailty items at the baseline, the only statistically significant difference was for the 
presence of low energy (p for trend <0.0001) (Table 1).  
 
Polypharmacy and incident frailty 
During the 8-year follow-up, 361 subjects (=8.2% of the baseline population) developed frailty 
equating to a global incidence rate of 23 (95%CI: 14-32)/1,000 persons-year (Figure 1). 
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Table 2 illustrates the association between the use of medications and incident frailty at follow-up. 
Taking those using fewer medications as the reference group (0-3 medications), those using 4-6 
medications had a doubled incidence of frailty, whilst participants using 7 medications or more had  
approximately a 6 times higher incidence of frailty. Using a Cox’s regression analysis, adjusted for 
11 potential confounders at baseline, participants using 4-6 medications had a higher risk of frailty 
of 55% (HR=1.55; 95%CI: 1.22-1.96; p<0.0001), whilst those using more than 7 drugs were almost 
at 150% increased risk of frailty (HR=2.47; 95%CI: 1.78-3.43; p<0.0001) (Table 2).  
 
Modelling the number of medications as continuous, each drug used at the baseline increased the 
risk of frailty at the follow-up of 11% (HR=1.11; 95%CI: 1.07-1.15; p<0.0001).  
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DISCUSSION 
In this study including more than 4,000 participants at baseline, we showed that polypharmacy was 
associated with higher risk of frailty over a follow-up of 8 years. After adjusting for 11 potential 
confounders (including the presence of co-morbidities) participants using 4-6 medications were at a 
55% higher risk of frailty as well as those consuming more than 7 medications had approximately a 
2.5-fold increased risk of developing frailty. Moreover, our analysis suggested a dose response 
relationship, with each additional medication being associated with an 11% increased risk of frailty. 
Altogether our findings suggest that polypharmacy is a common and potentially modifiable risk 
factor for frailty in the elderly.  
 
Our results are in agreement with the findings of other studies regarding the same topic. 6-8  Across 
1,662 men aged who were more than 70 years of age with a follow up period of two years, Gnjidic 
et al. found that the use of more than 5 medications is associated with incident frailty. 6 In a cohort 
with similar characteristics (n=1,705, follow up period =5 years), Jamsen et al. found that a higher 
number of medications was associated with greater risk of mortality in robust community-dwelling 
older men and with a higher risk of transitioning from the robust state to the prefrail state.7 Even if 
these two studies were important to understand the role of polypharmacy in promoting frailty, they 
did not included any comprehensive multimorbidity score as Saum et al. proposed more recently.8 
However, whilst Saum et al. considered the type and number of medical conditions at baseline, the 
association between polypharmacy and incident frailty remained significant. Compared to all these 
studies, we included the largest population to date with the longest follow-up. Moreover, we 
included younger people than those considered in the previous studies suggesting that the 
association between polypharmacy and frailty is also of importance in a younger population. It is 
noteworthy that our sensitivity analysis did not suggest a potential role of age in moderating our 
results. Finally, we adjusted our analyses also for nutritional parameters important for the 
association between polypharmacy and frailty, such as adherence to Mediterranean diet.23-25 
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Several reasons could explain the association between polypharmacy and incident frailty. First, 
polypharmacy may contribute to the development of frailty through a negative influence on factors 
associated with frailty (such as comorbidities) or factors included in frailty definitions such as 
weight loss. 26,27 Further, polypharmacy has been linked to inappropriate prescribing 28, low 
adherence 29, preventable and unplanned hospitalization 30 and adverse drug events 31, all relevant to 
the development of frailty. This is particularly relevant to older individuals, who are more 
susceptible to adverse drug reactions (ADRs) 32, also caused by commonly used medications. 32 
ADRs could further increase the risk of frailty as they might lead to a prescribing cascade, in which 
new medications are prescribed to counteract unwanted effects of the initial drug. (28) 
 
Whether altering the number of medications could have a role in decreasing the incidence of frailty 
remains an important and unresolved question. Participants taking higher number of medications 
are, obviously, unhealthier than those taking less medications. In the current analysis, there was 
unsurprisingly a significant association between medical comorbidity and increased number of 
medications. However it is notable that when comorbidity was included as a confounding variable, 
each additional medication was associated with an 11% increased risk of frailty. Therefore, this 
provides compelling evidence to reduce polypharmacy, especially where older people may be 
taking non-essential medications. It has been estimated that about 50% of older adults take one or 
more medications that are not medically necessary.33 Therefore, our findings, taken together with 
the wider established harms of polypharmacy, add to the growing need to evaluate the medication 
regimen for each individual treated with a high number of drugs. However, this should be done 
carefully since the beneficial effect of “deprescribing” has not been studied in randomized 
controlled trials, limiting our knowledge regarding this aspect.8 A comprehensive geriatric 
assessment (that includes validated tools and reliable prognostic instruments) 14,34-36 could be 
important to better understand and monitor the role of deprescribing in the onset of frailty.  
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The study does have some limitations, the main one being that we used a slightly different 
definition of frailty at baseline with respect to the one used at the follow-up as far as weight loss 
was concerned. Using that definition, only 20 participants were considered frail at baseline. 
Unfortunately, no data regarding weight changes were available in the OAI at the baseline and this 
could limit our definition of frailty at baseline. Second, although we know the number of 
medications used by every participant, we could only ascertain osteoarthritis specific medications 
used in OAI, such as pain-killers. Thus, we don’t know if there are some medications that could 
reduce the incidence of frailty. Finally, we were unable to assess the influence of bio-humoral 
markers (e.g. inflammation 37, insulin-resistance) on the association between polypharmacy and 
frailty. 
  
In conclusion, our data provides robust longitudinal evidence that polypharmacy is associated with 
higher incidence of frailty, even after adjusting for several important confounders. Moreover, our 
analyses suggest a dose response relationship. Future interventional studies are warranted to see if 
decreasing the number of medications (particularly if not necessary) could be associated with a 
lower incidence of this condition.    
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Table 1. Characteristics of the participants classified according to number of medications.  
 
0-3 medications 
(n=2862) 
4-6 medications 
(n=1236) 
>7 medications 
(n=304) 
P value for trenda 
Age (years) 60.0 (9.1) 63.7 (8.8) 63.7 (9.1) <0.0001 
Females (%) 54.3 64.3 68.4 <0.0001 
PASE (points) 171.6 (83.7) 144.0 (73.7) 129.6 (78.1) <0.0001 
White race (%) 80.8 80.4 76.6 <0.0001 
Smoking (previous/current) (%) 45.6 49.9 52.3 0.002 
College/degree (%) 31.1 29.8 27.3 0.14 
Yearly income (> $50,000) (%) 38.2 43.3 55.3 <0.0001 
BMI (Kg/m2) 28.2 (4.6) 29.3 (4.8) 30.5 (5.5) <0.0001 
Cardiovascular disease (%) 3.5 11.0 19.9 <0.0001 
COPD (%) 1.5 2.4 8.9 <0.0001 
Diabetes (%) 2.9 14.5 24.2 <0.0001 
Cancer (%) 4.5 4.8 8.6 0.02 
Charlson comorbidity index (points) 0.2 (0.7) 0.6 (1.0) 1.2 (1.4) <0.0001 
Energy intake (Kcal/day) 1417.6 (609.0) 1378.4 (543.7) 1429.1 (574.6) 0.03 
17 
 
 
0-3 medications 
(n=2862) 
4-6 medications 
(n=1236) 
>7 medications 
(n=304) 
P value for trenda 
aMED (points) 28.2 (5.1) 28.0 (4.9) 27.8 (5.1) 0.33 
BMI< 18.5 Kg/m2 2.4 1.9 2.3 0.57 
Inability to do five chair stands 0.6 0.7 1.3 0.24 
Low energy level 9.1 12.1 24.7 <0.0001 
 
Notes: The data are presented as means (with standard deviations) for continuous variables and number (with percentage).  
a P values for trends were calculated using the Jonckheere-Terpstra test for continuous variables and the Mantel-Haenszel Chi-square test for 
categorical ones.  
Abbreviations: aMED: adherence to Mediterranean diet score; PASE: Physical Activity Scale for the Elderly; BMI: body mass index; COPD: 
chronic obstructive pulmonary disease.  
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Table 2. Association between number of medications and incident frailty.  
 
Cumulative 
incidence 
(%) 
Incidence 
(95% CI) 
Unadjusted 
HR 
(95%CI) 
P value 
Fully-adjusteda 
HR 
(95%CI) 
P value 
0-3 medications 164/2862 (=5.7) 8 (7-10) 1 [reference] 1 [reference] 
4-6 medications 137/1236 (=11.1) 15 (12-18) 2.00 (1.60-2.52) <0.0001 1.55 (1.22-1.96) <0.0001 
> 7 medications 60/304 (=19.7) 46 (20-73) 3.92 (2.90-5.29) <0.0001 2.47 (1.78-3.43) <0.0001 
 
Notes: 
All the data are presented as hazard ratios (HRs) with their 95% confidence intervals. 
 
aFully-adjusted model included as covariates: age (as continuous); sex; race (whites vs. others); body mass index (as continuous); education (degree 
vs. others); smoking habits (current and previous vs. others); yearly income (categorized as > or < 50,000$ and missing data); Physical Activity 
Scale for Elderly score (as continuous);  Charlson co-morbidity index; daily energy intake; adherence to Mediterranean diet.   
 
Abbreviations:  CI: confidence intervals; HR: hazard ratio.
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Figure 1. Risk of frailty by number of medications at the baseline.  
 
 
